Page last updated: 2024-08-16

linsidomine and 5-((4-prop-2-ynylpiperazin-1-yl)methyl)quinolin-8-ol

linsidomine has been researched along with 5-((4-prop-2-ynylpiperazin-1-yl)methyl)quinolin-8-ol in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Amit, T; Carri, MT; Kupershmidt, L; Mandel, S; Weinreb, O; Youdim, MB	1

Other Studies

1 other study(ies) available for linsidomine and 5-((4-prop-2-ynylpiperazin-1-yl)methyl)quinolin-8-ol

Article	Year
Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, Volume: 23, Issue:11 Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; GAP-43 Protein; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hydrogen Peroxide; Hydroxyquinolines; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Mice; Mice, Transgenic; Molsidomine; Motor Neurons; Neurites; Neuroprotective Agents; Phosphopyruvate Hydratase; Piperazines; Proto-Oncogene Proteins c-akt; Receptors, Transferrin; Signal Transduction; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A	2009

Article

Year

Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2009, Volume: 23, Issue:11

Topics: Amyotrophic Lateral Sclerosis; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; Cell Differentiation; Cell Line; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; GAP-43 Protein; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hydrogen Peroxide; Hydroxyquinolines; Hypoxia-Inducible Factor 1, alpha Subunit; Iron Chelating Agents; Mice; Mice, Transgenic; Molsidomine; Motor Neurons; Neurites; Neuroprotective Agents; Phosphopyruvate Hydratase; Piperazines; Proto-Oncogene Proteins c-akt; Receptors, Transferrin; Signal Transduction; Superoxide Dismutase; Superoxide Dismutase-1; Vascular Endothelial Growth Factor A

2009